Product Description
Mechanisms of Action: G-Secretase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-002758-39 | P3 |
Completed |
Alzheimer Disease |
2011-07-11 |
|
LY450139 Versus Placebo | P3 |
Completed |
Alzheimer Disease |
2011-05-01 |
|
2009-014424-29 | P3 |
Completed |
Alzheimer Disease |
2011-04-15 |
|
2007-005118-37 | P3 |
Terminated |
Alzheimer Disease |
2011-04-12 |